Date: 2016-02-25
Type of information: Collaboration agreement
Compound: industrial manufacturing platform for adeno-associated virus (AAV) production
Company: Cobra Biologics (Sweden) Centre for Process Innovation (CPI) (UK)
Therapeutic area: Technology - Services
Type agreement: collaboration production manufacturing
Action mechanism:
Disease:
Details: * On February 25, 2016, Cobra Biologics, an international CDMO of biologics and pharmaceuticals, and the Centre for Process Innovation (CPI), a UK-based technology innovation centre, are collaborating on a project which will focus on the development of an Industrial Manufacturing Platform for Adeno-Associated Virus (AAV) production to support gene therapy and regenerative medicine.
The collaboration between Cobra and CPI will focus on AAV vectors which are safe and effective and are currently the delivery vehicle of choice for gene therapy treatments. However the advancement of these therapies into clinical trials is currently hampered by the lack of robust scalability needed to manufacture AAV vectors.
The proposed collaboration between Cobra and CPI will develop in depth scientific and technical understanding to allow a scalable and flexible manufacturing process to be developed to produce, purify and characterise a range of AAV vectors. This will enable the acceleration of more potential products into clinical testing and ultimately new medicines. This in turn will increase the chances of treatments being developed for a whole range of currently intractable diseases.
Financial terms: The £1.8M project, which is being led by Cobra, is being funded to a value of £1.4M by Innovate UK via their 2015 competition for the development of regenerative medicines and cell therapies. The project is one of five which together comprise an £8 million investment into collaborative R&D projects that address critical challenges faced by UK companies developing regenerative medicines and cell therapies as clinical treatments and commercial products.
Latest news:
